These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7695294)

  • 1. Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.
    Barclay ML; Begg EJ; Chambers ST; Boswell DR
    Antimicrob Agents Chemother; 1995 Jan; 39(1):132-6. PubMed ID: 7695294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gentamicin dosing regimens using an in-vitro model.
    Begg EJ; Peddie BA; Chambers ST; Boswell DR
    J Antimicrob Chemother; 1992 Apr; 29(4):427-33. PubMed ID: 1607331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of successive exposure of Pseudomonas aeruginosa to gentamicin and ceftazidime.
    Shibl AM; Tawfik AF; Ramadan MA
    Int J Antimicrob Agents; 1997 May; 8(4):257-61. PubMed ID: 18611812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
    Mouton JW; den Hollander JG
    Antimicrob Agents Chemother; 1994 May; 38(5):931-6. PubMed ID: 8067772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
    Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.
    Barclay ML; Begg EJ; Chambers ST
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1951-7. PubMed ID: 1416886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):64-8. PubMed ID: 3929682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
    Pruekprasert P; Tunyapanit W
    Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro.
    Gerber AU; Wiprächtiger P; Stettler-Spichiger U; Lebek G
    J Infect Dis; 1982 Apr; 145(4):554-60. PubMed ID: 6802906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
    Valdes JM; Baltch AL; Smith RP; Hammer MC; Ritz WJ
    J Antimicrob Chemother; 1990 Apr; 25(4):575-84. PubMed ID: 2112539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal activity of ceftazidime against Pseudomonas aeruginosa under conditions simulating serum pharmacokinetic.
    Shah PM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():135-40. PubMed ID: 19802977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa.
    Moore KW; Trepanier LA; Lautzenhiser SJ; Fialkowski JP; Rosin E
    Am J Vet Res; 2000 Oct; 61(10):1204-8. PubMed ID: 11039548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents.
    Dan M; Zabeeda D; Poch F
    Chemotherapy; 1995; 41(5):323-9. PubMed ID: 8521732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of bactericidal curves in the optimal selection of a beta-lactam-aminoglycoside combination on Pseudomonas aeruginosa. In vitro study of 40 strains of Pseudomonas aeruginosa isolated in pediatric intensive care units].
    Lambert-Zechovsky N; Bingen E; Guihaire E; Nancy C; Mercier JC; Beaufils F
    Presse Med; 1986 Dec; 15(46):2309-12. PubMed ID: 2949273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.
    Cappelletty DM
    Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.
    Tisdale JE; Pasko MT; Mylotte JM
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1500-5. PubMed ID: 2510592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.
    Karlowsky JA; Zhanel GG; Davidson RJ; Hoban DJ
    Antimicrob Agents Chemother; 1994 May; 38(5):1165-8. PubMed ID: 8067757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.